Zacks Investment Research upgraded shares of CORCEPT THERAPT (CORT) from NEUTRAL to OUTPERFORM on October 09, 2014, with a target price of $3.00.
Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol. It is developing its lead product, CORLUX for the treatment of the psychotic features of psychotic major depression. Corcept Therapeutics Incorporated is headquartered in Menlo Park, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CORCEPT THERAPT (CORT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment